Professor Sir Mike Stratton, FMedSci FRS | Institute Director

Mike Stratton is the Director of the Wellcome Trust Sanger Institute and Chief Executive Officer of the Wellcome Genome Campus.

His primary research interests have been in the genetics of cancer. His early research focused on inherited susceptibility. Mike mapped and identified the major high-risk breast cancer susceptibility gene BRCA2 and subsequently a series of moderate-risk breast cancer and other cancer susceptibility genes. 

In 2000 Mike initiated the Cancer Genome Project at the Wellcome Trust Sanger Institute which conducts systematic genome-wide searches for somatic mutations in human cancer. Through these studies he discovered somatic mutations of the BRAF gene in malignant melanoma and several other mutated cancer genes in lung, renal, breast and other cancers. He has described the basic patterns of somatic mutation in cancer genomes revealing underlying DNA mutational and repair processes.

Mike is a Fellow of the Royal Society (FRS) and was Knighted by the Queen in 2013. 

Publications

  • A germline mutation in the androgen receptor gene in two brothers with breast cancer and Reifenstein syndrome.

    Wooster R, Mangion J, Eeles R, Smith S, Dowsett M et al.

    Nature genetics 1992;2;2;132-4

  • Instability of short tandem repeats (microsatellites) in human cancers.

    Wooster R, Cleton-Jansen AM, Collins N, Mangion J, Cornelis RS et al.

    Nature genetics 1994;6;2;152-6

  • Familial male breast cancer is not linked to the BRCA1 locus on chromosome 17q.

    Stratton MR, Ford D, Neuhasen S, Seal S, Wooster R et al.

    Nature genetics 1994;7;1;103-7

  • Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13.

    Wooster R, Neuhausen SL, Mangion J, Quirk Y, Ford D et al.

    Science (New York, N.Y.) 1994;265;5181;2088-90

  • Familial cylindromatosis (turban tumour syndrome) gene localised to chromosome 16q12-q13: evidence for its role as a tumour suppressor gene.

    Biggs PJ, Wooster R, Ford D, Chapman P, Mangion J et al.

    Nature genetics 1995;11;4;441-3

  • Identification of the breast cancer susceptibility gene BRCA2.

    Wooster R, Bignell G, Lancaster J, Swift S, Seal S et al.

    Nature 1995;378;6559;789-92

  • Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium.

    No authors listed

    Lancet (London, England) 1997;349;9064;1505-10

  • Identification of the familial cylindromatosis tumour-suppressor gene.

    Bignell GR, Warren W, Seal S, Takahashi M, Rapley E et al.

    Nature genetics 2000;25;2;160-5

  • Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations.

    Meijers-Heijboer H, van den Ouweland A, Klijn J, Wasielewski M, de Snoo A et al.

    Nature genetics 2002;31;1;55-9

  • Mutations of the BRAF gene in human cancer.

    Davies H, Bignell GR, Cox C, Stephens P, Edkins S et al.

    Nature 2002;417;6892;949-54

  • Lung cancer: intragenic ERBB2 kinase mutations in tumours.

    Stephens P, Hunter C, Bignell G, Edkins S, Davies H et al.

    Nature 2004;431;7008;525-6

  • PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene.

    Rahman N, Seal S, Thompson D, Kelly P, Renwick A et al.

    Nature genetics 2007;39;2;165-7

  • Patterns of somatic mutation in human cancer genomes.

    Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C et al.

    Nature 2007;446;7132;153-8

  • Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer.

    van Haaften G, Dalgliesh GL, Davies H, Chen L, Bignell G et al.

    Nature genetics 2009;41;5;521-3

  • A genome-wide association study of testicular germ cell tumor.

    Rapley EA, Turnbull C, Al Olama AA, Dermitzakis ET, Linger R et al.

    Nature genetics 2009;41;7;807-10

  • A systematic, large-scale resequencing screen of X-chromosome coding exons in mental retardation.

    Tarpey PS, Smith R, Pleasance E, Whibley A, Edkins S et al.

    Nature genetics 2009;41;5;535-43

  • Complex landscapes of somatic rearrangement in human breast cancer genomes.

    Stephens PJ, McBride DJ, Lin ML, Varela I, Pleasance ED et al.

    Nature 2009;462;7276;1005-10

  • Signatures of mutation and selection in the cancer genome.

    Bignell GR, Greenman CD, Davies H, Butler AP, Edkins S et al.

    Nature 2010;463;7283;893-8

  • Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes.

    Dalgliesh GL, Furge K, Greenman C, Chen L, Bignell G et al.

    Nature 2010;463;7279;360-3

  • A comprehensive catalogue of somatic mutations from a human cancer genome.

    Pleasance ED, Cheetham RK, Stephens PJ, McBride DJ, Humphray SJ et al.

    Nature 2010;463;7278;191-6

  • Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma.

    Varela I, Tarpey P, Raine K, Huang D, Ong CK et al.

    Nature 2011;469;7331;539-42

  • Genome sequencing and analysis of the Tasmanian devil and its transmissible cancer.

    Murchison EP, Schulz-Trieglaff OB, Ning Z, Alexandrov LB, Bauer MJ et al.

    Cell 2012;148;4;780-91

  • The landscape of cancer genes and mutational processes in breast cancer.

    Stephens PJ, Tarpey PS, Davies H, Van Loo P, Greenman C et al.

    Nature 2012;486;7403;400-4

  • Mutational processes molding the genomes of 21 breast cancers.

    Nik-Zainal S, Alexandrov LB, Wedge DC, Van Loo P, Greenman CD et al.

    Cell 2012;149;5;979-93

  • Signatures of mutational processes in human cancer.

    Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S et al.

    Nature 2013;500;7463;415-21

  • Transmissible [corrected] dog cancer genome reveals the origin and history of an ancient cell lineage.

    Murchison EP, Wedge DC, Alexandrov LB, Fu B, Martincorena I et al.

    Science (New York, N.Y.) 2014;343;6169;437-40

  • Association of a germline copy number polymorphism of APOBEC3A and APOBEC3B with burden of putative APOBEC-dependent mutations in breast cancer.

    Nik-Zainal S, Wedge DC, Alexandrov LB, Petljak M, Butler AP et al.

    Nature genetics 2014;46;5;487-91

  • Genome sequencing of normal cells reveals developmental lineages and mutational processes.

    Behjati S, Huch M, van Boxtel R, Karthaus W, Wedge DC et al.

    Nature 2014;513;7518;422-5

  • Mutational signatures associated with tobacco smoking in human cancer.

    Alexandrov LB, Ju YS, Haase K, Van Loo P, Martincorena I et al.

    Science (New York, N.Y.) 2016;354;6312;618-622

  • Tissue-specific mutation accumulation in human adult stem cells during life.

    Blokzijl F, de Ligt J, Jager M, Sasselli V, Roerink S et al.

    Nature 2016;538;7624;260-264

  • Breast cancer genome and transcriptome integration implicates specific mutational signatures with immune cell infiltration.

    Smid M, Rodríguez-González FG, Sieuwerts AM, Salgado R, Prager-Van der Smissen WJ et al.

    Nature communications 2016;7;12910

  • Mutational signatures of ionizing radiation in second malignancies.

    Behjati S, Gundem G, Wedge DC, Roberts ND, Tarpey PS et al.

    Nature communications 2016;7;12605

  • Direct Transcriptional Consequences of Somatic Mutation in Breast Cancer.

    Shlien A, Raine K, Fuligni F, Arnold R, Nik-Zainal S et al.

    Cell reports 2016;16;7;2032-46

  • A Landscape of Pharmacogenomic Interactions in Cancer.

    Iorio F, Knijnenburg TA, Vis DJ, Bignell GR, Menden MP et al.

    Cell 2016;166;3;740-54

  • A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers.

    Ferrari A, Vincent-Salomon A, Pivot X, Sertier AS, Thomas E et al.

    Nature communications 2016;7;12222

  • The topography of mutational processes in breast cancer genomes.

    Morganella S, Alexandrov LB, Glodzik D, Zou X, Davies H et al.

    Nature communications 2016;7;11383

  • Landscape of somatic mutations in 560 breast cancer whole-genome sequences.

    Nik-Zainal S, Davies H, Staaf J, Ramakrishna M, Glodzik D et al.

    Nature 2016;534;7605;47-54

  • Timing, rates and spectra of human germline mutation.

    Rahbari R, Wuster A, Lindsay SJ, Hardwick RJ, Alexandrov LB et al.

    Nature genetics 2016;48;2;126-33

  • Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents.

    Merlevede J, Droin N, Qin T, Meldi K, Yoshida K et al.

    Nature communications 2016;7;10767

  • Pharmacogenomic agreement between two cancer cell line data sets.

    Cancer Cell Line Encyclopedia Consortium and Genomics of Drug Sensitivity in Cancer Consortium

    Nature 2015;528;7580;84-7

  • Clock-like mutational processes in human somatic cells.

    Alexandrov LB, Jones PH, Wedge DC, Sale JE, Campbell PJ et al.

    Nature genetics 2015;47;12;1402-7

  • SETD2 loss-of-function promotes renal cancer branched evolution through replication stress and impaired DNA repair.

    Kanu N, Grönroos E, Martinez P, Burrell RA, Yi Goh X et al.

    Oncogene 2015;34;46;5699-708

  • The genome as a record of environmental exposure.

    Nik-Zainal S, Kucab JE, Morganella S, Glodzik D, Alexandrov LB et al.

    Mutagenesis 2015;30;6;763-70

  • A mutational signature in gastric cancer suggests therapeutic strategies.

    Alexandrov LB, Nik-Zainal S, Siu HC, Leung SY and Stratton MR

    Nature communications 2015;6;8683

  • Subclonal diversification of primary breast cancer revealed by multiregion sequencing.

    Yates LR, Gerstung M, Knappskog S, Desmedt C, Gundem G et al.

    Nature medicine 2015;21;7;751-9

  • Frequent somatic transfer of mitochondrial DNA into the nuclear genome of human cancer cells.

    Ju YS, Tubio JM, Mifsud W, Fu B, Davies HR et al.

    Genome research 2015;25;6;814-24

  • Tumor evolution. High burden and pervasive positive selection of somatic mutations in normal human skin.

    Martincorena I, Roshan A, Gerstung M, Ellis P, Van Loo P et al.

    Science (New York, N.Y.) 2015;348;6237;880-6

  • Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets.

    Schulze K, Imbeaud S, Letouzé E, Alexandrov LB, Calderaro J et al.

    Nature genetics 2015;47;5;505-11

  • Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue.

    Cooper CS, Eeles R, Wedge DC, Van Loo P, Gundem G et al.

    Nature genetics 2015;47;4;367-72

  • Combined hereditary and somatic mutations of replication error repair genes result in rapid onset of ultra-hypermutated cancers.

    Shlien A, Campbell BB, de Borja R, Alexandrov LB, Merico D et al.

    Nature genetics 2015;47;3;257-62

  • Multi-stage genome-wide association study identifies new susceptibility locus for testicular germ cell tumour on chromosome 3q25.

    Litchfield K, Sultana R, Renwick A, Dudakia D, Seal S et al.

    Human molecular genetics 2015;24;4;1169-76

  • BCL11A is a triple-negative breast cancer gene with critical functions in stem and progenitor cells.

    Khaled WT, Choon Lee S, Stingl J, Chen X, Raza Ali H et al.

    Nature communications 2015;6;5987

  • Combinations of PARP Inhibitors with Temozolomide Drive PARP1 Trapping and Apoptosis in Ewing's Sarcoma.

    Gill SJ, Travers J, Pshenichnaya I, Kogera FA, Barthorpe S et al.

    PloS one 2015;10;10;e0140988

  • COSMIC: exploring the world's knowledge of somatic mutations in human cancer.

    Forbes SA, Beare D, Gunasekaran P, Leung K, Bindal N et al.

    Nucleic acids research 2015;43;Database issue;D805-11

  • High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma.

    Linnemann C, van Buuren MM, Bies L, Verdegaal EM, Schotte R et al.

    Nature medicine 2015;21;1;81-5

  • C. elegans whole-genome sequencing reveals mutational signatures related to carcinogens and DNA repair deficiency.

    Meier B, Cooke SL, Weiss J, Bailly AP, Alexandrov LB et al.

    Genome research 2014;24;10;1624-36

  • Origins and functional consequences of somatic mitochondrial DNA mutations in human cancer.

    Ju YS, Alexandrov LB, Gerstung M, Martincorena I, Nik-Zainal S et al.

    eLife 2014;3

  • Genome sequencing of normal cells reveals developmental lineages and mutational processes.

    Behjati S, Huch M, van Boxtel R, Karthaus W, Wedge DC et al.

    Nature 2014;513;7518;422-5

  • Mobile DNA in cancer. Extensive transduction of nonrepetitive DNA mediated by L1 retrotransposition in cancer genomes.

    Tubio JM, Li Y, Ju YS, Martincorena I, Cooke SL et al.

    Science (New York, N.Y.) 2014;345;6196;1251343

  • Association of a germline copy number polymorphism of APOBEC3A and APOBEC3B with burden of putative APOBEC-dependent mutations in breast cancer.

    Nik-Zainal S, Wedge DC, Alexandrov LB, Petljak M, Butler AP et al.

    Nature genetics 2014;46;5;487-91

  • Processed pseudogenes acquired somatically during cancer development.

    Cooke SL, Shlien A, Marshall J, Pipinikas CP, Martincorena I et al.

    Nature communications 2014;5;3644

  • Constitutional and somatic rearrangement of chromosome 21 in acute lymphoblastic leukaemia.

    Li Y, Schwab C, Ryan SL, Papaemmanuil E, Robinson HM et al.

    Nature 2014;508;7494;98-102

  • Recurrent PTPRB and PLCG1 mutations in angiosarcoma.

    Behjati S, Tarpey PS, Sheldon H, Martincorena I, Van Loo P et al.

    Nature genetics 2014;46;4;376-9

  • RAG-mediated recombination is the predominant driver of oncogenic rearrangement in ETV6-RUNX1 acute lymphoblastic leukemia.

    Papaemmanuil E, Rapado I, Li Y, Potter NE, Wedge DC et al.

    Nature genetics 2014;46;2;116-25

  • Mutational signatures: the patterns of somatic mutations hidden in cancer genomes.

    Alexandrov LB and Stratton MR

    Current opinion in genetics & development 2014;24;52-60

  • Transmissible [corrected] dog cancer genome reveals the origin and history of an ancient cell lineage.

    Murchison EP, Wedge DC, Alexandrov LB, Fu B, Martincorena I et al.

    Science (New York, N.Y.) 2014;343;6169;437-40

  • A pathogenic mosaic TP53 mutation in two germ layers detected by next generation sequencing.

    Behjati S, Maschietto M, Williams RD, Side L, Hubank M et al.

    PloS one 2014;9;5;e96531

  • A proteomic chronology of gene expression through the cell cycle in human myeloid leukemia cells.

    Ly T, Ahmad Y, Shlien A, Soroka D, Mills A et al.

    eLife 2014;3;e01630

  • Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone.

    Behjati S, Tarpey PS, Presneau N, Scheipl S, Pillay N et al.

    Nature genetics 2013;45;12;1479-82

  • Clinical and biological implications of driver mutations in myelodysplastic syndromes.

    Papaemmanuil E, Gerstung M, Malcovati L, Tauro S, Gundem G et al.

    Blood 2013;122;22;3616-27; quiz 3699

  • Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma.

    van Rooij N, van Buuren MM, Philips D, Velds A, Toebes M et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013;31;32;e439-42

  • Signatures of mutational processes in human cancer.

    Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S et al.

    Nature 2013;500;7463;415-21

  • Genome-wide mutational signatures of aristolochic acid and its application as a screening tool.

    Poon SL, Pang ST, McPherson JR, Yu W, Huang KK et al.

    Science translational medicine 2013;5;197;197ra101

  • Frequent mutation of the major cartilage collagen gene COL2A1 in chondrosarcoma.

    Tarpey PS, Behjati S, Cooke SL, Van Loo P, Wedge DC et al.

    Nature genetics 2013;45;8;923-6

  • Single-cell paired-end genome sequencing reveals structural variation per cell cycle.

    Voet T, Kumar P, Van Loo P, Cooke SL, Marshall J et al.

    Nucleic acids research 2013;41;12;6119-38

  • Whole exome sequencing of adenoid cystic carcinoma.

    Stephens PJ, Davies HR, Mitani Y, Van Loo P, Shlien A et al.

    The Journal of clinical investigation 2013;123;7;2965-8

  • Identification of nine new susceptibility loci for testicular cancer, including variants near DAZL and PRDM14.

    Ruark E, Seal S, McDonald H, Zhang F, Elliot A et al.

    Nature genetics 2013;45;6;686-9

  • DNA deaminases induce break-associated mutation showers with implication of APOBEC3B and 3A in breast cancer kataegis.

    Taylor BJ, Nik-Zainal S, Wu YL, Stebbings LA, Raine K et al.

    eLife 2013;2;e00534

  • Deciphering signatures of mutational processes operative in human cancer.

    Alexandrov LB, Nik-Zainal S, Wedge DC, Campbell PJ and Stratton MR

    Cell reports 2013;3;1;246-59

  • Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells.

    Yang W, Soares J, Greninger P, Edelman EJ, Lightfoot H et al.

    Nucleic acids research 2013;41;Database issue;D955-61

  • Bayesian refinement of association signals for 14 loci in 3 common diseases.

    Wellcome Trust Case Control Consortium, Maller JB, McVean G, Byrnes J, Vukcevic D et al.

    Nature genetics 2012;44;12;1294-301

  • The life history of 21 breast cancers.

    Nik-Zainal S, Van Loo P, Wedge DC, Alexandrov LB, Greenman CD et al.

    Cell 2012;149;5;994-1007

  • The landscape of cancer genes and mutational processes in breast cancer.

    Stephens PJ, Tarpey PS, Davies H, Van Loo P, Greenman C et al.

    Nature 2012;486;7403;400-4

  • Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma.

    Varela I, Tarpey P, Raine K, Huang D, Ong CK et al.

    Nature 2011;469;7331;539-42

  • Massive genomic rearrangement acquired in a single catastrophic event during cancer development.

    Stephens PJ, Greenman CD, Fu B, Yang F, Bignell GR et al.

    Cell 2011;144;1;27-40

  • Natural history of Christianson syndrome.

    Schroer RJ, Holden KR, Tarpey PS, Matheus MG, Griesemer DA et al.

    American journal of medical genetics. Part A 2010;152A;11;2775-83

  • The patterns and dynamics of genomic instability in metastatic pancreatic cancer.

    Campbell PJ, Yachida S, Mudie LJ, Stephens PJ, Pleasance ED et al.

    Nature 2010;467;7319;1109-13

  • Variants near DMRT1, TERT and ATF7IP are associated with testicular germ cell cancer.

    Turnbull C, Rapley EA, Seal S, Pernet D, Renwick A et al.

    Nature genetics 2010;42;7;604-7

  • Constitutional translocation breakpoint mapping by genome-wide paired-end sequencing identifies HACE1 as a putative Wilms tumour susceptibility gene.

    Slade I, Stephens P, Douglas J, Barker K, Stebbings L et al.

    Journal of medical genetics 2010;47;5;342-7

  • International network of cancer genome projects.

    International Cancer Genome Consortium, Hudson TJ, Anderson W, Artez A, Barker AD et al.

    Nature 2010;464;7291;993-8

  • Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls.

    Wellcome Trust Case Control Consortium, Craddock N, Hurles ME, Cardin N, Pearson RD et al.

    Nature 2010;464;7289;713-20

  • Epilepsy and mental retardation limited to females with PCDH19 mutations can present de novo or in single generation families.

    Hynes K, Tarpey P, Dibbens LM, Bayly MA, Berkovic SF et al.

    Journal of medical genetics 2010;47;3;211-6

  • Signatures of mutation and selection in the cancer genome.

    Bignell GR, Greenman CD, Davies H, Butler AP, Edkins S et al.

    Nature 2010;463;7283;893-8

  • Novel candidate cancer genes identified by a large-scale cross-species comparative oncogenomics approach.

    Mattison J, Kool J, Uren AG, de Ridder J, Wessels L et al.

    Cancer research 2010;70;3;883-95

  • Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes.

    Dalgliesh GL, Furge K, Greenman C, Chen L, Bignell G et al.

    Nature 2010;463;7279;360-3

  • A comprehensive catalogue of somatic mutations from a human cancer genome.

    Pleasance ED, Cheetham RK, Stephens PJ, McBride DJ, Humphray SJ et al.

    Nature 2010;463;7278;191-6

  • A small-cell lung cancer genome with complex signatures of tobacco exposure.

    Pleasance ED, Stephens PJ, O'Meara S, McBride DJ, Meynert A et al.

    Nature 2010;463;7278;184-90

  • COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer.

    Forbes SA, Tang G, Bindal N, Bamford S, Dawson E et al.

    Nucleic acids research 2010;38;Database issue;D652-7

  • A genome-wide association study of testicular germ cell tumor.

    Rapley EA, Turnbull C, Al Olama AA, Dermitzakis ET, Linger R et al.

    Nature genetics 2009;41;7;807-10

  • A systematic, large-scale resequencing screen of X-chromosome coding exons in mental retardation.

    Tarpey PS, Smith R, Pleasance E, Whibley A, Edkins S et al.

    Nature genetics 2009;41;5;535-43

  • Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2.

    Ahmed S, Thomas G, Ghoussaini M, Healey CS, Humphreys MK et al.

    Nature genetics 2009;41;5;585-90

  • Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer.

    van Haaften G, Dalgliesh GL, Davies H, Chen L, Bignell G et al.

    Nature genetics 2009;41;5;521-3

  • The cancer genome.

    Stratton MR, Campbell PJ and Futreal PA

    Nature 2009;458;7239;719-24

  • Subclonal phylogenetic structures in cancer revealed by ultra-deep sequencing.

    Campbell PJ, Pleasance ED, Stephens PJ, Dicks E, Rance R et al.

    Proceedings of the National Academy of Sciences of the United States of America 2008;105;35;13081-6

  • Identification of somatically acquired rearrangements in cancer using genome-wide massively parallel paired-end sequencing.

    Campbell PJ, Stephens PJ, Pleasance ED, O'Meara S, Li H et al.

    Nature genetics 2008;40;6;722-9

  • X-linked protocadherin 19 mutations cause female-limited epilepsy and cognitive impairment.

    Dibbens LM, Tarpey PS, Hynes K, Bayly MA, Scheffer IE et al.

    Nature genetics 2008;40;6;776-81

  • The Catalogue of Somatic Mutations in Cancer (COSMIC).

    Forbes SA, Bhamra G, Bamford S, Dawson E, Kok C et al.

    Current protocols in human genetics 2008;Chapter 10;Unit 10.11

  • Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants.

    Wellcome Trust Case Control Consortium, Australo-Anglo-American Spondylitis Consortium (TASC), Burton PR, Clayton DG, Cardon LR et al.

    Nature genetics 2007;39;11;1329-37

  • Mutations in UPF3B, a member of the nonsense-mediated mRNA decay complex, cause syndromic and nonsyndromic mental retardation.

    Tarpey PS, Raymond FL, Nguyen LS, Rodriguez J, Hackett A et al.

    Nature genetics 2007;39;9;1127-33

  • Genome-wide association study identifies novel breast cancer susceptibility loci.

    Easton DF, Pooley KA, Dunning AM, Pharoah PD, Thompson D et al.

    Nature 2007;447;7148;1087-93

  • Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers.

    Maser RS, Choudhury B, Campbell PJ, Feng B, Wong KK et al.

    Nature 2007;447;7147;966-71

  • Mutations in ZDHHC9, which encodes a palmitoyltransferase of NRAS and HRAS, cause X-linked mental retardation associated with a Marfanoid habitus.

    Raymond FL, Tarpey PS, Edkins S, Tofts C, O'Meara S et al.

    American journal of human genetics 2007;80;5;982-7

  • Patterns of somatic mutation in human cancer genomes.

    Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C et al.

    Nature 2007;446;7132;153-8

  • PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene.

    Rahman N, Seal S, Thompson D, Kelly P, Renwick A et al.

    Nature genetics 2007;39;2;165-7

  • Mutation analysis of 24 known cancer genes in the NCI-60 cell line set.

    Ikediobi ON, Davies H, Bignell G, Edkins S, Stevens C et al.

    Molecular cancer therapeutics 2006;5;11;2606-12

  • Mutations in FRMD7, a newly identified member of the FERM family, cause X-linked idiopathic congenital nystagmus.

    Tarpey P, Thomas S, Sarvananthan N, Mallya U, Lisgo S et al.

    Nature genetics 2006;38;11;1242-4

  • Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles.

    Seal S, Thompson D, Renwick A, Elliott A, Kelly P et al.

    Nature genetics 2006;38;11;1239-41

  • ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles.

    Renwick A, Thompson D, Seal S, Kelly P, Chagtai T et al.

    Nature genetics 2006;38;8;873-5

  • A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy.

    Hunter C, Smith R, Cahill DP, Stephens P, Stevens C et al.

    Cancer research 2006;66;8;3987-91

  • COSMIC 2005.

    Forbes S, Clements J, Dawson E, Bamford S, Webb T et al.

    British journal of cancer 2006;94;2;318-22

  • Somatic mutations of the protein kinase gene family in human lung cancer.

    Davies H, Hunter C, Smith R, Stephens P, Greenman C et al.

    Cancer research 2005;65;17;7591-5

  • A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer.

    Stephens P, Edkins S, Davies H, Greenman C, Cox C et al.

    Nature genetics 2005;37;6;590-2

  • Lung cancer: intragenic ERBB2 kinase mutations in tumours.

    Stephens P, Hunter C, Bignell G, Edkins S, Davies H et al.

    Nature 2004;431;7008;525-6

  • The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website.

    Bamford S, Dawson E, Forbes S, Clements J, Pettett R et al.

    British journal of cancer 2004;91;2;355-8

  • Cancer: understanding the target.

    Stratton MR and Futreal PA

    Nature 2004;430;6995;30

  • A census of human cancer genes.

    Futreal PA, Coin L, Marshall M, Down T, Hubbard T et al.

    Nature reviews. Cancer 2004;4;3;177-83

  • Mutations of the BRAF gene in human cancer.

    Davies H, Bignell GR, Cox C, Stephens P, Edkins S et al.

    Nature 2002;417;6892;949-54

  • Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations.

    Meijers-Heijboer H, van den Ouweland A, Klijn J, Wasielewski M, de Snoo A et al.

    Nature genetics 2002;31;1;55-9

  • Cancer and genomics.

    Futreal PA, Kasprzyk A, Birney E, Mullikin JC, Wooster R and Stratton MR

    Nature 2001;409;6822;850-2

  • Identification of the familial cylindromatosis tumour-suppressor gene.

    Bignell GR, Warren W, Seal S, Takahashi M, Rapley E et al.

    Nature genetics 2000;25;2;160-5

  • Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium.

    No authors listed

    Lancet (London, England) 1997;349;9064;1505-10

Stratton, Mike
Sir Mike's Timeline
2015

The 2016 Mike Price Gold Medal Award, European Association of Cancer Research

2014

Fellow of the AACR Academy

The ESHG Award, European Society of Human Genetics

2013

The Louis-Jeantet Prize for Medicine

Knighted in the Queen's Birthday Honours List

The GHA Clowes Award, American Association of Cancer Research, USA

The Ernst W Bertner Award, MD Anderson Cancer Centre

The Sergio Lombroso Award in Cancer Research, Weizmann Institute

The AACR Distinguished Lecturer in Breast Cancer Research Award

2012

Royal Physiographical Society Medal, Lund, Sweden

Estella Medrano Memorial Lecture Award, Society for Melanoma Research

Appointed Chief Executive Officer of the Wellcome Genome Campus.

2011

The Massachusetts General Hospital Award in Cancer Research

2010

The C. Chester Stock Award, Memorial Sloan Kettering Cancer Centre

Member of EMBO

Appointed as the Director of the Sanger Institute

The Lila Gruber Award for Cancer Research, American Academy of Dermatology

2009

Member of the European Molecular Biology Organisation

2008

Fellow of the Royal Society

The BioMedicum Helsinki Medal, Finland

2007

Appointed as Deputy Director of the Sanger Institute

The AstraZeneca Award, Biochemical Society

2002

The Lennox K Black Award for Excellence in Medicine, Thomas Jefferson University

2001

The Tom Connors Award, British Association of Cancer Research

2000

Initiated the Cancer Genome Project and became the Head of this Programme

Member of the Sanger Institute's Board of Management

1999

Fellow of the Academy of Medical Sciences

1997

Appointed as Professor of Cancer Genetics and Chair of the newly constitute section of Cancer Genetics at the Institute of Cancer Research

1996

Reader in the Molecular Genetics of Cancer, Institute of Cancer Research

1992

Honorary Consultant, Royal Marsden Hospital

1991

Team Leader in Molecular Carcinogenesis at the Institute of Cancer Research

Obtained the MRCPath and qualified as a Consultant Pathologist - Hammersmith and Maudsley Hospital

1989

Senior Registrar, Department of Neuropathology, Institute of Psychiatry

1986

MRC Training Fellow, Institute of Cancer Research and Institute of Psychiatry

Conducted research for a PhD on the molecular biology of cancer at the Institute Cancer Research

1984

Senior House Office - Pathology - Westminster Hospital

Trained as a histopathologist

1983

Research Fellow, Institute of Psychiatry

1982

House Surgeon at Guys Hospital

House Physician at Beckenham Hospital

1979

Qualified in medicine at Oxford